Blastic Plasmacytoid Dendritic Cell Neoplasm Market To Reach $214.27 Million By 2030

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Growth & Trends

The global blastic plasmacytoid dendritic cell neoplasm market size is anticipated to reach USD 214.27 million by 2030 and is projected to grow at a CAGR of 7.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses a range of elements critical to diagnosing, treating, and managing this rare hematological malignancy.

The incidence of BPDCN is increasing, attributed to better diagnostic methods and heightened awareness among healthcare providers and patients. This rise in incidence boosts the demand for effective treatments. Significant advancements in understanding BPDCN’s molecular and genetic aspects led to the development of targeted therapies, with promising drugs undergoing clinical trials.

BPDCN is classified as an orphan disease in various regions, encouraging pharmaceutical investment through incentives such as extended market exclusivity and tax credits. The shift towards personalized medicine enhances treatment strategies based on genetic profiles, expanding the market for customized therapies.

 Request a free sample copy or view report summary: Blastic Plasmacytoid Dendritic Cell Neoplasm Market Report

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Report Highlights

• Based on treatment, Chemotherapy dominated the market with the largest revenue share of 38.7% in 2023. Combining chemotherapy with novel agents such as tagraxofusp transforms BPDCN treatment. This highlights chemotherapy's pivotal role and drives market growth through improved outcomes and the introduction of targeted therapies.

• Based on end use, hospitals dominated the market with the largest revenue share of 57.5% in 2023. The rising incidence of BPDCN, estimated at 1,000 to 1,400 cases annually in the U.S. and Europe, increased hospital visits. Advanced diagnostic tools and specialized oncology departments facilitate timely and accurate diagnoses essential for effective treatment initiation.

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Segmentation

Grand View Research has segmented global blastic plasmacytoid dendritic cell neoplasm market based on the basis of treatment, end use, and region:

Blastic Plasmacytoid Dendritic Cell Neoplasm Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Chemotherapy

• Immunotherapy

• Stem Cell Transplantation

• Targeted Therapy

• Other

Blastic Plasmacytoid Dendritic Cell Neoplasm End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Specialty Clinics

• Other

Blastic Plasmacytoid Dendritic Cell Neoplasm Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Blastic Plasmacytoid Dendritic Cell Neoplasm Market

• AbbVie Inc.

• ImmunoGen, Inc.

• Mustang Bio

• Genentech, Inc.

• Stemline Therapeutics, Inc.

• Jazz Pharmaceuticals, Inc.

• Cellex Patient Treatment GmbH

• Xencor

• Resverlogix